Funded Startups in Newton
Across the 30 most recent Newton-area funded entries (2020-04-20 through 2026-06-30), the disclosed round sizes show a clear long tail: Xellar Biosystems r…
Across the 30 most recent Newton-area funded entries (2020-04-20 through 2026-06-30), the disclosed round sizes show a clear long tail: Xellar Biosystems raised $30M in 2026-06-30 (Series A), but the next-largest disclosed amounts in the list are $40M (DUST Identity, 2023-12-05) and $165M (Karyopharm Therapeutics, 2022-12-05), making Karyopharm’s $165M an outlier that dwarfs nearly all other disclosed rounds (the bulk cluster sits under $60M, with multiple entries at $4M–$28M). Sectorally, biotechnology and health-related work dominate: biotechnology appears in 6 of 30 rows (Xellar Biosystems; Inflammasome Therapeutics; Gelmedix; Acer Therapeutics; Karyopharm Therapeutics; Stealth BioTherapeutics; plus Zikani Therapeutics), while health care also repeats across 7 of 30 rows (Alleviate; HouseWorks; Family Access Of Newton; Agile Devices; Meetcaregivers; Courage Therapeutics; and others). The list is also stage-uncertain for a large share of rounds: “Series Unknown” appears 10 times and “undisclosed” amounts appear 4 times, with several recent entries (e.g., Inflammasome Therapeutics at $13M on 2026-05-04) providing partial disclosure. Temporally, entries cluster around the late-2022 peak (multiple 2022 rounds including Karyopharm at $165M on 2022-12-05 and Abcuro’s $42M on 2021-01-07), while the most recent disclosed row is Xellar Biosystems (2026-06-30) and the oldest is Zikani Therapeutics (2020-04-20).
Most recent rounds
30 shownRelated listings
Frequently asked
Which Newton-area disclosed round is the outlier, and how does it compare to the rest of the list?
Karyopharm Therapeutics is the standout with a $165M disclosed amount on 2022-12-05 (Series Unknown). The next-largest disclosed amounts are $60M (First Help Financial, 2021-11-17) and $42M (Abcuro, 2021-01-07), while many other disclosed rounds are in the $1M–$30M range (e.g., Xellar Biosystems $30M on 2026-06-30 and DUST Identity $40M on 2023-12-05).
How concentrated are these rounds in time, and what does the date spread look like?
The shown rounds span from 2020-04-20 (Zikani Therapeutics) through 2026-06-30 (Xellar Biosystems). There’s notable density in 2021–2023, including multiple entries in late 2022 (e.g., PaxeraHealth on 2022-12-12, Karyopharm Therapeutics on 2022-12-05, and others in December 2022), suggesting a clustered funding window rather than a steady cadence.
Are certain stages or disclosure categories over-represented in Newton funding here?
“Series Unknown” appears in 10 of 30 rows (e.g., Inflammasome Therapeutics on 2026-05-04 at $13M; Alleviate on 2023-02-15 at $4M; and others), and “undisclosed” amounts appear in 4 rows (e.g., MelliCell on 2024-10-24; Family Access Of Newton on 2023-06-21). The combination means the list frequently lacks both stage detail and/or disclosed dollar figures when analysts compare deal sizes.
Do any sectors show repeated presence across the 30 entries?
Biotechnology shows up in 7 of 30 rows (Xellar Biosystems; Inflammasome Therapeutics; Gelmedix; Acer Therapeutics; Karyopharm Therapeutics; Stealth BioTherapeutics; Zikani Therapeutics). Health Care is also prominent with 7 of 30 rows (including Alleviate on 2023-02-15, HouseWorks on 2023-01-12, and Courage Therapeutics on 2021-03-24), indicating sector clustering toward life sciences rather than a balanced tech mix.
Which city pattern appears, given the Newton label ambiguity?
Most entries are explicitly “Newton, Massachusetts,” but there is at least one different geography under the same Newton label: Sussex County Community College is listed as “Newton, New Jersey” on 2023-07-13 (Series Unknown) with $10K. All other rows in the list that show a disclosed amount are tied to Newton, Massachusetts, including the largest disclosed deals (e.g., Karyopharm Therapeutics in Newton, Massachusetts).
What does the most recent 90-day window look like by count and deal size disclosure?
Using the most recent date in the list (2026-06-30), entries within roughly the prior 90 days include Xellar Biosystems (2026-06-30, $30M), Inflammasome Therapeutics (2026-05-04, $13M), and Zydro Marine Technologies (2026-04-14, $2M). All three are disclosed on amount, but their stages vary (Series A vs. Series Unknown vs. Seed), so the recent window is not dominated by a single stage classification.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.